BioPharma Resources

Drug Trial Radar · NCT07319845

A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes

A Phase 2, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of TAK-226 for Anemia in Japanese Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Apr 22, 2026

Primary completion

Jun 26, 2028

Study completion Jan 10, 2033

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jan 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of the study is to evaluate how TAK-226 improves symptoms of transfusion-dependent anemia in Japanese patients with lower-risk myelodysplastic syndromes. The study consists of Screening Period (up to 6 weeks), Treatment Period, Safety Follow-Up Period (8 weeks), and Long-Term Follow-Up Period (approximately 5 years from the first dose of the study treatment). Participants of this study will be administered TAK-226 during Treatment Period. Subsequently, the participants will be monitored for side effects related to the study treatment during Safety Follow-Up Period and Long-Term Follow-Up Period. The approximate duration of participation for a participant is up to approximately 6 years. During the study period, participants will visit the study clinic/hospital multiple times as per the study schedule. During Treatment Period, the participants will come to the clinic/hospital approximately every two to four weeks.

Conditions

  • Myelodysplastic Syndromes

Interventions

  • TAK-226Drug

    TAK-226 subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Transfusion dependent (TD) cohort: Percentage of Participants Achieving Transfusion Independence (TI) for Greater Than or Equal to (>=) 8 Weeks from Baseline through Week 24Time frame: Baseline, Up to Week 24
  2. Non-transfusion dependent (NTD) cohort: Percentage of Participants Achieving Mean Hgb Increase of >=1.5 grams per deciliter (g/dL) for >=8 Weeks from Baseline through Week 24 And No RBC Transfusion during the Same >=8 Weeks PeriodTime frame: Baseline, Up to Week 24

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, Japan · Recruiting

  • Gifu Municipal Hospital

    Gifu, Japan · Recruiting

  • Japanese Red Cross Nagasaki Genbaku Hospital

    Nagasaki, Japan · Not yet recruiting

  • Okayama City General Medical Center Okayama City Hospital

    Okayama, Japan · Not yet recruiting

  • Yamagata University Hospital

    Yamagata, Japan · Recruiting

  • Tokyo Metropolitan Komagome Hospital

    Tokyo, Bunkyo-ku, Japan · Recruiting

  • University of Fukui Hospital

    Fukui, Eiheiji, Japan · Recruiting

  • Japan Mutual Aid Association of Public School Teachers Chugoku Central Hospital

    Hiroshima, Fukuyama, Japan · Recruiting

  • Tokai University Hospital

    Kanagawa, Isehara, Japan · Not yet recruiting

  • JCHO Kyushu Hospital

    Fukuoka, Kitakyushu, Japan · Recruiting

  • Kobe City Hospital Organization Kobe City Medical Center General Hospital

    Hyōgo, Kobe, Japan · Not yet recruiting

  • Yamanashi Prefectural Central Hospital

    Yamanashi, Kofu, Japan · Not yet recruiting

  • Matsuyama Red Cross Hospital

    Ehime, Matsuyama, Japan · Recruiting

  • Dokkyo Medical University Hospital

    Tochigi, Mibu, Japan · Not yet recruiting

  • National Hospital Organization Nagoya Medical Center

    Aichi, Nagoya, Japan · Not yet recruiting

  • Japanese Red Cross Narita Hospital

    Chiba, Narita, Japan · Not yet recruiting

  • Kitasato University Hospital

    Kanagawa, Sagamihara, Japan · Not yet recruiting

  • Kindai University Hospital

    Osaka, Sakai, Japan · Recruiting

  • Hokuyukai Sapporo Hokuyu Hospital

    Hokkaido, Sapporo, Japan · Recruiting

  • National University Corporation Tohoku University Tohoku University Hospital

    Miyagi, Sendai, Japan · Not yet recruiting

  • NTT Medical Center Tokyo

    Tokyo, Shinagawa-ku, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.